Published: 2014-07-14 18:47:13
Michael Kozlowski OD, PHD, Chief Science Officer
Kalos Therapeutics, Inc dedicated to treating patients not just their diseases. Kalos is a peptide therapeutic company treating virulent cancers and the related comorbidities. The Kalos solution focuses in putting tumor cells into a prolonged non dividing state, also treating the ascites and edema that lead to pain and death. Kalos drugs engage known pathway receptors in the MAPK pathway and it does so more efficiently without the side effects associated with chemotherapeutic compounds. As confirmed in an Investigator IND our clinical effects of increased natriuresis and diuresis will treat the related comorbidities of cancer reducing ascites, and edema, as well as shrinking the tumor.